BioNexus Gene Lab (NASDAQ:BGLC) Releases Quarterly Earnings Results

BioNexus Gene Lab (NASDAQ:BGLC) announced its quarterly earnings data on Friday. The company reported ($0.39) EPS for the quarter, Zacks reports. BioNexus Gene Lab had a negative net margin of 30.70% and a negative return on equity of 35.54%.

BioNexus Gene Lab Price Performance

Shares of BGLC traded up $0.01 during midday trading on Friday, hitting $4.53. 14,643 shares of the company traded hands, compared to its average volume of 899,736. BioNexus Gene Lab has a one year low of $2.01 and a one year high of $15.60. The firm has a market cap of $8.15 million, a P/E ratio of -7.95 and a beta of 5.19. The stock has a 50-day moving average of $5.23 and a 200-day moving average of $4.67.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of BioNexus Gene Lab in a report on Thursday, October 30th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, BioNexus Gene Lab presently has an average rating of “Sell”.

BioNexus Gene Lab Company Profile

BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers.